S
Samaresh Sau
Researcher at Eugene Applebaum College of Pharmacy and Health Sciences
Publications - 73
Citations - 3372
Samaresh Sau is an academic researcher from Eugene Applebaum College of Pharmacy and Health Sciences. The author has contributed to research in topics: Cancer & Drug delivery. The author has an hindex of 24, co-authored 72 publications receiving 2315 citations. Previous affiliations of Samaresh Sau include Purdue University & Wayne State University.
Papers
More filters
Journal ArticleDOI
PD-1 and PD-L1 Checkpoint Signaling Inhibition for Cancer Immunotherapy: Mechanism, Combinations, and Clinical Outcome.
Hashem O. Alsaab,Hashem O. Alsaab,Samaresh Sau,Rami Alzhrani,Rami Alzhrani,Katyayani Tatiparti,Ketki Bhise,Sushil K. Kashaw,Sushil K. Kashaw,Arun K. Iyer,Arun K. Iyer +10 more
TL;DR: The current landscape of the PD-1/PD-L1 mechanistic role in tumor immune evasion and therapeutic outcome for cancer treatment is reviewed and the current progress in clinical trials, combination of drug therapy with immunotherapy, safety, and future of check point inhibitors for multiple types of cancer are reviewed.
Journal ArticleDOI
siRNA Delivery Strategies: A Comprehensive Review of Recent Developments.
Katyayani Tatiparti,Samaresh Sau,Sushil K. Kashaw,Sushil K. Kashaw,Arun K. Iyer,Arun K. Iyer +5 more
TL;DR: This review presents a comprehensive update on the challenges of siRNA delivery and the current strategies used to develop nanoparticulate delivery systems.
Journal ArticleDOI
Multifunctional nanoparticles for cancer immunotherapy: A groundbreaking approach for reprogramming malfunctioned tumor environment.
Samaresh Sau,Hashem O. Alsaab,Ketki Bhise,Rami Alzhrani,Ghazal Nabil,Arun K. Iyer,Arun K. Iyer +6 more
TL;DR: The role of multifunctional polymeric, lipid, metallic and cell based nanoparticles for improving current immunotherapy and the function of host immune stimulatory signals and tumor immunotherapies can be improved by repurposing of nanomedicine platform are summarized.
Journal ArticleDOI
Polyvalent Folate-Dendrimer-Coated Iron Oxide Theranostic Nanoparticles for Simultaneous Magnetic Resonance Imaging and Precise Cancer Cell Targeting.
TL;DR: A novel strategy to engineer a polyvalent theranostic nanocarrier consisting of superparamagnetic iron oxide nanoparticle core (SPIONs) decorated with folic acid-polyamidoamine dendrimers surface (FA-PAMAM) and targeted nanoparticles showed higher accumulation with a better anticancer activity as compared to the nontargeted counterparts.
Journal ArticleDOI
Advances in antibody-drug conjugates: A new era of targeted cancer therapy.
Samaresh Sau,Hashem O. Alsaab,Sushil K. Kashaw,Katyayani Tatiparti,Arun K. Iyer,Arun K. Iyer +5 more
TL;DR: With advances in bioengineering, linker chemistry, and potent cytotoxic payload, ADC technology has become a more powerful tool for targeted cancer therapy and ADCs with improved safety using humanized Abs with a unified 'drug:antibody ratio' (DAR) have been achieved.